FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555762053> ?p ?o ?g. }

• W2555762053 endingPage "847" @default.
• W2555762053 startingPage "847.2" @default.
• W2555762053 abstract "<h3>Background</h3> Biologic therapies (bDMARDs) have improved the treatment of rheumatic diseases; however, the risk of tuberculosis (TB) infection or reactivation in patients treated with this drug class remains a concern. <h3>Objectives</h3> We investigated the clinical characteristics and prognostic factors of TB in an Argentine registry of rheumatic diseases patients treated with bDMARDS. <h3>Methods</h3> Database included demographics of patients, type and duration of treatments and clinical information of adverse events. A control group was included for comparison consisting of patients not treated with bDMARDs but similar demographics. Values are expressed as mean±standard deviation, median (ranges), and frequencies (percentages), as appropriate. Multivariate logistic regression analysis was used to identify variables associated with the occurrence of TB; OR and 95% CI were calculated by exponentiation of regression coefficients. <h3>Results</h3> As of January 2016, 3483 patients, 4762 treatments and 2580 adverse events were studied. Mean age 56.1±15,7 years; 2748 (78.9%) patients were women. Initial treatments were 1472 (42.3) bDMARD <i>vs.</i> 2011 (57.7) non-bDMARD. Main diagnosis: Rheumatoid arthritis (RA) 2706 (77.7), Psoriatic arthritis (PsA) 293 (8.4), juvenile idiopathic arthritis (JIA) and lupus with 117 (3.36) each. Of 4762 treatments, most frequent biological drugs were etanercept 119 (25,1), adalimumab 626 (13,2), and abatacept with 282 (5.9). Of 3483 patients, 18 (0.5) presented TB as an adverse event, their mean age was 52.9±2.8; 16 (88.9) had AR and 2 (11.1) had PsA; 16 (88.9) had initially received bDMARD vs. 2 (11.1) who had received non- bDMARD treatments. PPD test was performed in 2002/2883 (69.4) bDMARD treatments vs. 372/1879 (19.8%) non-bDMARD treatments, with 126 (6.3) vs 35 (9.4) positive tests, respectively. Median time from treatment commencement to TB was 15.1 (range 1.6–137.5) months. Treatments during which, TB was diagnosed were etanercept 5 (27.8), adalimumab 4 (22.2), non-bDMARD 3 (16.7), abatacept and infliximab with 2 (11.1) each and tocilizumab 1 (5.6), the distribution was not significantly different (Table 1). The risk of developing TB was higher in patients whose first treatment was bDMARDs (OR 5.6 95%CI 1.3–24.3). <h3>Conclusions</h3> A higher frequency of TB was seen in patients treated with bDMARDs; however, results should be interpreted cautiously because of registries inherent limitations. <h3>Disclosure of Interest</h3> None declared" @default.
• W2555762053 created "2016-11-30" @default.
• W2555762053 creator A5002873199 @default.
• W2555762053 creator A5002990109 @default.
• W2555762053 creator A5004255872 @default.
• W2555762053 creator A5005868336 @default.
• W2555762053 creator A5007830675 @default.
• W2555762053 creator A5008076200 @default.
• W2555762053 creator A5010396678 @default.
• W2555762053 creator A5014193021 @default.
• W2555762053 creator A5016113175 @default.
• W2555762053 creator A5017064455 @default.
• W2555762053 creator A5021434503 @default.
• W2555762053 creator A5022320110 @default.
• W2555762053 creator A5025378766 @default.
• W2555762053 creator A5027956662 @default.
• W2555762053 creator A5029021270 @default.
• W2555762053 creator A5035664085 @default.
• W2555762053 creator A5037073032 @default.
• W2555762053 creator A5040220945 @default.
• W2555762053 creator A5040468988 @default.
• W2555762053 creator A5041885719 @default.
• W2555762053 creator A5044324844 @default.
• W2555762053 creator A5048372362 @default.
• W2555762053 creator A5049529784 @default.
• W2555762053 creator A5052301856 @default.
• W2555762053 creator A5057520257 @default.
• W2555762053 creator A5059833626 @default.
• W2555762053 creator A5060072103 @default.
• W2555762053 creator A5061072112 @default.
• W2555762053 creator A5061649632 @default.
• W2555762053 creator A5067613942 @default.
• W2555762053 creator A5074008345 @default.
• W2555762053 creator A5076036222 @default.
• W2555762053 creator A5076659440 @default.
• W2555762053 creator A5077434380 @default.
• W2555762053 creator A5077829185 @default.
• W2555762053 creator A5081464857 @default.
• W2555762053 creator A5082237505 @default.
• W2555762053 creator A5085868926 @default.
• W2555762053 creator A5086632584 @default.
• W2555762053 creator A5087724859 @default.
• W2555762053 creator A5088978266 @default.
• W2555762053 date "2016-06-01" @default.
• W2555762053 modified "2023-09-27" @default.
• W2555762053 title "SAT0488 Tuberculosis in A Registry of Rheumatic Patients Treated with Biological Drugs" @default.
• W2555762053 doi "https://doi.org/10.1136/annrheumdis-2016-eular.4029" @default.
• W2555762053 hasPublicationYear "2016" @default.
• W2555762053 type Work @default.
• W2555762053 sameAs 2555762053 @default.
• W2555762053 citedByCount "0" @default.
• W2555762053 crossrefType "journal-article" @default.
• W2555762053 hasAuthorship W2555762053A5002873199 @default.
• W2555762053 hasAuthorship W2555762053A5002990109 @default.
• W2555762053 hasAuthorship W2555762053A5004255872 @default.
• W2555762053 hasAuthorship W2555762053A5005868336 @default.
• W2555762053 hasAuthorship W2555762053A5007830675 @default.
• W2555762053 hasAuthorship W2555762053A5008076200 @default.
• W2555762053 hasAuthorship W2555762053A5010396678 @default.
• W2555762053 hasAuthorship W2555762053A5014193021 @default.
• W2555762053 hasAuthorship W2555762053A5016113175 @default.
• W2555762053 hasAuthorship W2555762053A5017064455 @default.
• W2555762053 hasAuthorship W2555762053A5021434503 @default.
• W2555762053 hasAuthorship W2555762053A5022320110 @default.
• W2555762053 hasAuthorship W2555762053A5025378766 @default.
• W2555762053 hasAuthorship W2555762053A5027956662 @default.
• W2555762053 hasAuthorship W2555762053A5029021270 @default.
• W2555762053 hasAuthorship W2555762053A5035664085 @default.
• W2555762053 hasAuthorship W2555762053A5037073032 @default.
• W2555762053 hasAuthorship W2555762053A5040220945 @default.
• W2555762053 hasAuthorship W2555762053A5040468988 @default.
• W2555762053 hasAuthorship W2555762053A5041885719 @default.
• W2555762053 hasAuthorship W2555762053A5044324844 @default.
• W2555762053 hasAuthorship W2555762053A5048372362 @default.
• W2555762053 hasAuthorship W2555762053A5049529784 @default.
• W2555762053 hasAuthorship W2555762053A5052301856 @default.
• W2555762053 hasAuthorship W2555762053A5057520257 @default.
• W2555762053 hasAuthorship W2555762053A5059833626 @default.
• W2555762053 hasAuthorship W2555762053A5060072103 @default.
• W2555762053 hasAuthorship W2555762053A5061072112 @default.
• W2555762053 hasAuthorship W2555762053A5061649632 @default.
• W2555762053 hasAuthorship W2555762053A5067613942 @default.
• W2555762053 hasAuthorship W2555762053A5074008345 @default.
• W2555762053 hasAuthorship W2555762053A5076036222 @default.
• W2555762053 hasAuthorship W2555762053A5076659440 @default.
• W2555762053 hasAuthorship W2555762053A5077434380 @default.
• W2555762053 hasAuthorship W2555762053A5077829185 @default.
• W2555762053 hasAuthorship W2555762053A5081464857 @default.
• W2555762053 hasAuthorship W2555762053A5082237505 @default.
• W2555762053 hasAuthorship W2555762053A5085868926 @default.
• W2555762053 hasAuthorship W2555762053A5086632584 @default.
• W2555762053 hasAuthorship W2555762053A5087724859 @default.
• W2555762053 hasAuthorship W2555762053A5088978266 @default.
• W2555762053 hasConcept C126322002 @default.
• W2555762053 hasConcept C197934379 @default.
• W2555762053 hasConcept C2776260265 @default.
• W2555762053 hasConcept C2777226972 @default.
• W2555762053 hasConcept C2777575956 @default.

• next